Validation of the Appropriate Use Criteria for Percutaneous Coronary Intervention in Patients With Stable Coronary Artery Disease (from the COURAGE Trial)-Reference-Cited by-同舟云学术

Validation of the Appropriate Use Criteria for Percutaneous Coronary Intervention in Patients With Stable Coronary Artery Disease (from the COURAGE Trial)

Published:2015-07 Issue:2 Volume:116 Page:167-173
ISSN:0002-9149
Container-title:The American Journal of Cardiology
language:en
Short-container-title:The American Journal of Cardiology

Author:

Bradley Steven M.^ORCID,Chan Paul S.,Hartigan Pamela M.,Nallamothu Brahmajee K.,Weintraub William S.,Sedlis Steven P.,Dada Marcin,Maron David J.,Kostuk William J.,Berman Daniel S.,Teo Koon K.,Mancini G.B. John,Boden William E.,Spertus John A.

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference29 articles.

1. ACCF/SCAI/STS/AATS/AHA/ASNC/HFSA/SCCT 2012 Appropriate Use Criteria for Coronary Revascularization Focused Update

2. Percutaneous coronary intervention use in the United States defining measures of appropriateness;Marso;JACC Cardiovasc Interv,2012

3. Appropriate use criteria to reduce underuse and overuse of revascularization;Kereiakes;J Am Coll Cardiol,2013

4. Optimal medical therapy with or without PCI for stable coronary disease;Boden;N Engl J Med,2007

5. Design and rationale of the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) Trial Veterans Affairs cooperative studies program no. 424;Boden;Am Heart J,2006

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Modified Delphi panel consensus recommendations for management of severe aplastic anemia;Blood Advances;2024-07-26

2. Characteristics and efficacy of traditional Chinese medicine in the therapeutic strategy of chronic coronary syndrome: A systematic review and meta-analysis;Phytomedicine;2024-07

3. Expert Consensus Recommendations on the Management of Treatment-emergent Adverse Events Among Men with Prostate Cancer Taking Poly-ADP Ribose Polymerase Inhibitor + Novel Hormonal Therapy Combination Therapy;European Urology Oncology;2024-06

4. Expert consensus on the management of infusion-related reactions (IRRs) in patients with sickle cell disease (SCD) receiving crizanlizumab: a RAND/UCLA modified Delphi panel;Annals of Hematology;2024-04-20

5. Appropriateness of Percutaneous Coronary Interventions: A Systematic Review and Meta-Analysis;Journal of Cardiovascular Development and Disease;2023-02-21